Abstract 10P
Background
Non-coding RNAs (ncRNAs) have emerged as a significant theranostic agents in Breast Cancer (BC). These ncRNAs including microRNAs (miRNAs) play a fundamental role in regulating BC hallmarks and hold significant potential as diagnostic and prognostic biomarkers and therapeutic agents for non-metastatic BC thus perfectly fulfill the definition of theranostic agents. Moreover, ncRNAs offer advantages over traditional biomarkers as they provide greater accuracy and are less invasive nature. miR-1275 and miR-4317 have been reported by our group to act as tumor suppressor miRNAs in BC through repressing cellular migration, invasion and clonogenicity. However, miR-96 and miR-744 were spotted as aggressive oncomiRs in BC activating several oncogenic pathways. The aim of this study was to investigate the expression patterns of the aforementioned miRNAs in BC patients and to assess their role as theranostic agents through assessing their association with different clinical parameters.
Methods
BC patients (n=30) were recruited. BC tumors and their normal counterparts were resected. BC patients ‘age range (25-70 years old). Lymph node involvement, tumor grade, molecular subtype, ki-67 levels and PD-L1 surface expression were evaluated in all patients included in the study. RNA was extracted from biopsies, reverse transcribed and quantified using q-RT-PCR.
Results
OncomiRs: miR-744 and miR-96 were found to be overexpressed in BC tissues compared to their normal counterparts. While the tumor suppressor miRNAs: miR-1275 and miR-4317 was found to de downregulated in BC tissues. Upon assessing BC patients’ clinical parameter, it was found that miR-744 and miR-96 expression levels are correlated with high tumor grade (53%), positive lymphnode metastasis (63.3%). On the other hand, miR-1275 and miR-4317 reduced expression levels were found to be associated with PDL1+TNBC patients (60%). Yet, miR-744, miR-96 and miR-1275 levels were found to be higher in young BC patients.
Conclusions
This study highlights the involvement of paradoxically acting miRNAs in the differential diagnosis of BC subtypes and highlights their high prognostic potential. Moreover, it identifies the studied panel of miRNAs as novel theranostic agents in BC.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
L'Oréal-UNESCO For Women in Science.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
121P - DNA methylation co-operates with genomic alterations during non-small cell lung cancer evolution
Presenter: Nnenna Kanu
Session: Cocktail & Poster Display session
Resources:
Abstract
122P - Comprehensive multi-omics profiling identifies prognostic and predictive subtypes in renal cell carcinoma
Presenter: Sanha Park
Session: Cocktail & Poster Display session
Resources:
Abstract
123P - Copy number from ulcWGS to predict TNBC molecular subtypes in the IBCSG 22-00 trial
Presenter: Andrea Joaquin Garcia
Session: Cocktail & Poster Display session
Resources:
Abstract
124P - Targeting neoantigens in chronic lymphocytic leukemia (CLL) for personalized T cell therapy
Presenter: Gurvinder Kaur
Session: Cocktail & Poster Display session
Resources:
Abstract
125P - Detection and analysis of medulloblastoma subtype-specific copy number variations from RNA-seq data for improved risk-based subtype classification
Presenter: Ivan Martinez de Estibariz Royuela
Session: Cocktail & Poster Display session
Resources:
Abstract
126P - Genomic and transcriptomic profiles define smokers and non-smokers lung squamous cell carcinoma patients
Presenter: Matteo Canale
Session: Cocktail & Poster Display session
Resources:
Abstract
128P - Metastatic migrations in lung cancer: Insights from the PEACE autopsy programme
Presenter: Sonya Hessey
Session: Cocktail & Poster Display session
Resources:
Abstract
129P - NGS prescreening program for refractory solid tumors outside standard indications in a public network of cancer centers
Presenter: Paula Sàbat Viltró
Session: Cocktail & Poster Display session
Resources:
Abstract
130P - Transcriptomic analysis of patients with metastatic hormone-sensitive prostate cancer to identify genomic signatures involved in the transition from androgen-dependent to androgen-independent phenotype
Presenter: Giovanna Pecoraro
Session: Cocktail & Poster Display session
Resources:
Abstract
131P - Benchmarking whole exome sequencing in the German network for personalized medicine
Presenter: Michael Menzel
Session: Cocktail & Poster Display session
Resources:
Abstract